How much revenue does TetraLogic Pharmaceuticals make?

TetraLogic Pharmaceuticals reported $0 in revenue for fiscal year 2015. In Q3 2016 revenue was $0.

What companies are similar to TetraLogic Pharmaceuticals?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Australis Capital Inc. (AUSAF), Corix Bioscience, Inc. (CXBS), Neurobiological Technologies, Inc. (NTII), OncoVista Innovative Therapies, Inc. (OVIT).

TetraLogic Pharmaceuticals Corporation (TLOG) Stock

About TetraLogic Pharmaceuticals Corporation

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to ...

At a glance

TetraLogic Pharmaceuticals reported revenue of $0 for fiscal year 2015, and net income of -$49.72 million. In Q3 2016 (the quarter ended September 30, 2016) revenue was $0.

Figures from company filings; latest fiscal year ended December 31, 2015.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.